Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's
disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …

Importance Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging.
Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)–positive patients …

We report the case of a 79-year-old woman with Alzheimer's disease who participated in a
Phase III randomized controlled trial called CLARITY-AD testing the experimental drug …

Recent advances in Alzheimer disease (AD) therapeutics represent a step in the right
direction for patients with AD. In recent phase 3 trials for early symptomatic AD, lecanemab …

Alzheimer disease (AD) is the most common cause of dementia. The prevailing theory of the
underlying pathology assumes amyloid accumulation followed by tau protein aggregation …

The clinical benefit associated with anti-amyloid immunotherapies, a new class of drugs for
the treatment of Alzheimer's disease, is predicated on their ability to modify disease course …

The agency approved the drug through its accelerated approval pathway, stating that the
decision was based on phase 2 trial data that showed a reduction in amyloid β (Aβ) plaques …

Lecanemab, a novel amyloid-sequestering agent, recently received accelerated Food and
Drug Administration approval for the treatment of mild dementia due to Alzheimer disease …